CEFPOWER

Cefpodoxime proxetil is indicated for the trea tment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below :

• Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophil us influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains) .

• Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . 

• Community-acquired pneumonia caused by S. pneumoniae or H. influenzae (including beta-lactamase-producing strains) . 

• Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. ca tarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae .

• Acute, unco mplicated urethral and cervical gonorrhea caused by Ne isseria gonorrhoeae (including penicillinase-producing strains) .

• Acute, uncomplicated anorectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains) . 

• Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococ cus pyogenes . Abscesses should be surgically drained as clinically indicated .

• Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and M oraxella catarrhalis .

• Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus .